Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non–small-cell lung cancer
F Cappuzzo, FR Hirsch, E Rossi… - Journal of the …, 2005 - academic.oup.com
Background: Gefitinib is a selective inhibitor of the epidermal growth factor (EGFR) tyrosine
kinase, which is overexpressed in many cancers, including non–small-cell lung cancer …
kinase, which is overexpressed in many cancers, including non–small-cell lung cancer …
[HTML][HTML] Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib
FR Hirsch, M Varella-Garcia, F Cappuzzo, J McCoy… - Annals of …, 2007 - Elsevier
Background: Biological markers for optimal selection of patient to epidermal growth factor
receptor (EGFR)-targeted therapies are not established in advanced non-small-cell lung …
receptor (EGFR)-targeted therapies are not established in advanced non-small-cell lung …
Optimization of patient selection for gefitinib in non–small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt …
Purpose: Mutations in epidermal growth factor receptor (EGFR) are strongly predictive of
gefitinib efficacy in non–small-cell lung cancer. However, the presence of EGFR mutant …
gefitinib efficacy in non–small-cell lung cancer. However, the presence of EGFR mutant …
Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non–small cell …
TY Chou, CH Chiu, LH Li, CY Hsiao, CY Tzen… - Clinical cancer …, 2005 - AACR
Purpose: Mutations in epidermal growth factor receptor (EGFR) can be used to predict the
tumor response of patients receiving gefitinib for non–small cell lung cancer (NSCLC). We …
tumor response of patients receiving gefitinib for non–small cell lung cancer (NSCLC). We …
Predictive and prognostic impact of epidermal growth factor receptor mutation in non–small-cell lung cancer patients treated with gefitinib
Purpose This study was undertaken to investigate the effects of epidermal growth factor
receptor (EGFR) mutation and its downstream signaling on response and survival in non …
receptor (EGFR) mutation and its downstream signaling on response and survival in non …
Epidermal growth factor receptor messenger RNA expression, gene dosage, and gefitinib sensitivity in non–small cell lung cancer
R Dziadziuszko, SE Witta, F Cappuzzo, S Park… - Clinical Cancer …, 2006 - AACR
Purpose: Epidermal growth factor receptor (EGFR) mRNA expression and EGFR gene
dosage by quantitative PCR in tumor samples obtained from patients with gefitinib-treated …
dosage by quantitative PCR in tumor samples obtained from patients with gefitinib-treated …
Predictors of the Response to Gefitinib in Refractory Non–Small Cell Lung Cancer
KS Kim, JY Jeong, YC Kim, KJ Na, YH Kim, SJ Ahn… - Clinical cancer …, 2005 - AACR
Gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, has a
response rate of 10% to 20% in refractory non–small cell lung carcinoma. Although female …
response rate of 10% to 20% in refractory non–small cell lung carcinoma. Although female …
Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): study of a comprehensive panel of molecular markers
M Tiseo, G Rossi, M Capelletti, G Sartori, E Spiritelli… - Lung cancer, 2010 - Elsevier
A number of different clinical characteristics and molecular markers related to epidermal
growth factor receptor (EGFR) activation have been reported to singly correlate with …
growth factor receptor (EGFR) activation have been reported to singly correlate with …
Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non–small-cell lung cancer
FR Hirsch, M Varella-Garcia, PA Bunn Jr… - Journal of clinical …, 2006 - ascopubs.org
Purpose The phase III Iressa Survival Evaluation in Lung Cancer (ISEL) trial compared
gefitinib with placebo in 1,692 patients with refractory advanced non–small-cell lung cancer …
gefitinib with placebo in 1,692 patients with refractory advanced non–small-cell lung cancer …
Clinicopathologic features and prognostic implications of epidermal growth factor receptor (EGFR) gene copy number and protein expression in non-small cell lung …
YK Jeon, SW Sung, JH Chung, WS Park, JW Seo… - Lung cancer, 2006 - Elsevier
Increased epidermal growth factor receptor (EGFR) gene copy numbers and mutations
predict sensitivity to EGFR tyrosine kinase inhibitor in non-small cell lung cancer (NSCLC) …
predict sensitivity to EGFR tyrosine kinase inhibitor in non-small cell lung cancer (NSCLC) …